
While researchers saw no significant difference in metastasis-free survival with the use of perioperative apalutamide in patients undergoing radical prostatectomy based on conventional imaging alone, the addition of PSMA PET imaging revealed a 20 percent higher likelihood of metastasis-free survival with adjunctive apalutamide.



























